Summit Therapeutics' Ivonescimab Shows Improved Overall Survival in NSCLC Trial
Event summary
- Summit Therapeutics' ivonescimab plus chemotherapy demonstrated a hazard ratio of 0.76 in the updated overall survival analysis from the global Phase III HARMONi study, showing consistent efficacy across Western and Asian patients.
- The median follow-up time for Western patients increased to 23.2 months as of June 2026, with no additional safety signals noted.
- Summit's Biologics License Application (BLA) for ivonescimab has a PDUFA goal action date of November 14, 2026.
The big picture
Summit Therapeutics' updated analysis of ivonescimab in the HARMONi study reinforces the potential of bispecific antibodies in oncology, particularly for EGFR-mutated NSCLC. The consistent overall survival benefits observed across diverse patient populations could position ivonescimab as a key player in the evolving landscape of cancer therapeutics, pending regulatory approval.
What we're watching
- Regulatory Approval
- Whether the FDA will approve ivonescimab by the November 14, 2026 PDUFA date based on the updated overall survival data.
- Market Differentiation
- How Summit Therapeutics positions ivonescimab against existing EGFR-mutated NSCLC treatments in a competitive oncology market.
- Clinical Validation
- The pace at which additional detailed data from the HARMONi study will be presented at upcoming medical conferences and its impact on investor confidence.
Related topics